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Perez et al’s study using the Apple Watch to identify atrial fibrillation (AF) is a watershed moment 
in large-scale machine learning for wearable computing. Identifying relevant patients will be 
tremendously important to research in healthcare. For a condition like AF, this could reduce stroke 
risk by two thirds. 
 
Wearable sensing studies are interesting because they intersect two revolutionary technologies -- 
mobile computing and machine learning (ML). With 174 million smartwatches and 1.4 billion 
smartphones shipped in 2018 alone1,2, these devices create a unique opportunity to collect sensor 
data, particularly for health monitoring. Advances in ML enable researchers to turn these data into 
meaningful insights about patients; however, there is a tradeoff between the quantity and the quality 
of the data that is often overlooked. Specifically, obtaining large quantities of ground truth or gold 
standard data in wearable studies remains a key challenge of the field.  
 
In the study by Perez et al, only 450 out of 420,000 individuals had ground truth data. Their study 
excluded 417,000 participants using the irregular pulse notification. This design decision means their 
study was only able to report positive predictive value (PPV) and unable to explore sensitivity or 
specificity. In this editorial, we explore the difficulty of obtaining ground truth data and its 
implications for study design. 
 
There remains uncertainty as to the true accuracy of mobile and wearable devices. For example, how 
the accuracy of measures such as steps or heart rate from smartwatches  changes with various 
demographic covariates is an understudied question. The fundamental utility of consumer electronics 
in medicine has yet to be fully established, which is why we resort to gold standard devices, such as 
the ePatch used Perez et al’s study. Unfortunately, these devices are often burdensome; Perez et al 
received fewer ECG patches than anticipated. Additionally, deploying gold standard devices increases 
costs. Improvements to gold standard devices could make conducting studies easier. For participants, 
making these devices more comfortable and less prone to user error is and should continue to be a 
priority. To assist researchers, more gold standard devices should adopt standardized data formats, 
making obtaining and analyzing data easier. Ground truth devices enable studies like Perez et al’s 
 
1 https://www.statista.com/statistics/263437/global-smartphone-sales-to-end-users-since-2007 
2 https://www.statista.com/topics/4762/smartwatches/ 
 
  
that explores AF and Liaqat et al’s that explores respiratory rate using readily available consumer 
electronics. While these studies are interesting on their own, when their results are combined and 
applied to detecting higher level states such as acute exacerbations of COPD (Wu et al), they could 
bring about revolutionary changes to health management.  
 
These challenges with ground truth data are amplified when studying rare events. While wearable 
sensing studies collect vast amounts of data, only tiny fractions are relevant -- only 153 
(0.0000036%) participants with AF were identified among 420,000. This means studies have to be 
sufficiently large or run long enough to capture enough events of interest. However, a larger or 
longer study means that the cost and user burden of ground truth devices becomes proportionally 
larger. Rare events of interest can also be a challenge for machine learning where many models are 
sensitive to class imbalances. Various approaches exist to the problem of imbalanced datasets, and 
should be applied in practice, including synthetic oversampling, training regimens such as mixup, and 
regularization.  
 
One way to navigate these trade-offs is to be clear initially regarding the purpose of the study. A 
large consumer electronics company such as Apple may be interested in demonstrating that their 
devices do not cause unnecessary worry for users, nor burden to healthcare providers through false 
positives. For this objective, Perez et al’s study was well designed, since PPV was important, but 
sensitivity and specificity were not. They demonstrated that of 420,000 users, only 2000 received an 
alert and, of those with valid ECG data, 34% had an irregular pulse, which is sufficient evidence that 
the AF detection on the Apple watch provides more benefit than harm. For a study exploring COPD 
exacerbations (Wu et al), where the objective is to equip COPD patients with a smartwatch that 
notifies them of exacerbations, low sensitivity  would undermine the wearables key purpose. Limiting 
the population in the study to those with moderate to severe COPD who most need such an 
application increases the probability of observing exacerbations while reducing the overall study size. 
Furthermore, collecting ground truth data for only a small portion of the study can help overcome 
the cost and user burden challenges. These design decisions mitigate some of the challenges of 
ground truth data collection and enable reporting sensitivity. 
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